|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Emerging Treatments and Technologies |
Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients
Results of the Primary Prevention Project (PPP) trial
1 Department of Clinical Pharmacology and Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, S. Maria Imbaro (CH), Italy
2 Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Address correspondence and reprint requests to Antonio Nicolucci, MD, Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud Via Nazionale, 66030 S. Maria Imbaro (CH), Italy. E-mail: nicolucc{at}negrisud.it
OBJECTIVE—We investigated in general practice the efficacy of antiplatelets and antioxidants in primary prevention of cardiovascular events in people with type 2 diabetes.
RESEARCH DESIGN AND METHODS—The Primary Prevention Project (PPP) is a randomized, open trial with a two-by-two factorial design aimed to investigate low-dose aspirin (100 mg/day) and vitamin E (300 mg/day) in the prevention of cardiovascular events in patients with one or more cardiovascular risk factors. The primary end point was a composite end point of cardiovascular death, stroke, or myocardial infarction. A total of 1,031 people with diabetes in the PPP, aged 
50 years, without a previous cardiovascular event were enrolled by 316 general practitioners and 14 diabetes outpatient clinics.
RESULTS—The PPP trial was prematurely stopped (after a median of 3.7 years) by the independent data safety and monitoring board because of a consistent benefit of aspirin compared with the control group in a population of 4,495 patients with one or more major cardiovascular risk factors. In diabetic patients, aspirin treatment was associated with a nonsignificant reduction in the main end point (relative risk [RR] = 0.90, 95% CI 0.50–1.62) and in total cardiovascular events (0.89, 0.62–1.26) and with a nonsignificant increase in cardiovascular deaths (1.23, 0.69–2.19). In nondiabetic subjects, RRs for the main end point, total cardiovascular events, and cardiovascular deaths were 0.59 (0.37–0.94), 0.69 (0.53–0.90), and 0.32 (0.14–0.72), respectively. No significant reduction in any of the end points considered could be found with vitamin E in either diabetic or nondiabetic subjects.
CONCLUSIONS—Our data suggest a lower effect of primary prevention of cardiovascular disease (CVD) with low-dose aspirin in diabetic patients as opposed to subjects with other cardiovascular risk factors. If confirmed, these findings might indicate that the antiplatelet effects of aspirin in diabetic patients are overwhelmed by aspirin-insensitive mechanisms of platelet activation and thrombus formation, thus making the balance between benefits and harms of aspirin treatment unfavorable. Further large-scale trials investigating the role of aspirin in the primary prevention of CVD in diabetic patients are urgently needed.
Abbreviations: CVD, cardiovascular disease • ETDRS, Early Treatment of Diabetic Retinopathy Study • PPP, Primary Prevention Project • TIA, transient ischemic attack
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. L. Norris, D. Kansagara, C. Bougatsos, and R. Fu Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, June 3, 2008; 148(11): 855 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Gasparyan, T. Watson, and G. Y.H. Lip The Role of Aspirin in Cardiovascular Prevention: Implications of Aspirin Resistance J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1829 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Dora, C. K. Kramer, and L. H. Canani Standards of Medical Care in Diabetes--2008: Response to Hirsch, Inzucchi, and Kirkman Diabetes Care, May 1, 2008; 31(5): e44 - e44. [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes--2008 Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Woodward, D. Bayley, L. Overend, and G. Gill Antiplatelet drug use in a diabetic clinic QJM, September 1, 2007; 100(9): 547 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Stranges, J. R. Marshall, R. Natarajan, R. P. Donahue, M. Trevisan, G. F. Combs, F. P. Cappuccio, A. Ceriello, and M. E. Reid Effects of Long-Term Selenium Supplementation on the Incidence of Type 2 Diabetes: A Randomized Trial Ann Intern Med, August 21, 2007; 147(4): 217 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nicolucci, G. De Berardis, M. Sacco, and G. Tognoni AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions Eur. Heart J., August 2, 2007; 28(16): 1925 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kobayashi, K. Mao, H. Zheng, X. Wang, C. Patterson, T. D. O'Connell, and Q. Liang Diminished GATA4 Protein Levels Contribute to Hyperglycemia-induced Cardiomyocyte Injury J. Biol. Chem., July 27, 2007; 282(30): 21945 - 21952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nicolucci, G. De Berardis, M. Sacco, and G. Tognoni Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association: Response to Buse et al. Diabetes Care, June 1, 2007; 30(6): e57 - e57. [Full Text] [PDF]
|
|
|
|
|
|
A. Lapolla, F. Piarulli, G. Sartore, A. Ceriello, E. Ragazzi, R. Reitano, L. Baccarin, B. Laverda, and D. Fedele Advanced Glycation End Products and Antioxidant Status in Type 2 Diabetic Patients With and Without Peripheral Artery Disease Diabetes Care, March 1, 2007; 30(3): 670 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Buse, H. N. Ginsberg, G. L. Bakris, N. G. Clark, F. Costa, R. Eckel, V. Fonseca, H. C. Gerstein, S. Grundy, R. W. Nesto, et al. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association Circulation, January 2, 2007; 115(1): 114 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Razmara, P. Hjemdahl, M. Yngen, C.-G. Ostenson, N. H. Wallen, and N. Li Food Intake Enhances Thromboxane Receptor-Mediated Platelet Activation in Type 2 Diabetic Patients but Not in Healthy Subjects Diabetes Care, January 1, 2007; 30(1): 138 - 140. [Full Text] [PDF]
|
|
|
|
|
|
J. B. Buse, H. N. Ginsberg, G. L. Bakris, N. G. Clark, F. Costa, R. Eckel, V. Fonseca, H. C. Gerstein, S. Grundy, R. W. Nesto, et al. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association Diabetes Care, January 1, 2007; 30(1): 162 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Czernichow, A. Couthouis, S. Bertrais, A.-C. Vergnaud, L. Dauchet, P. Galan, and S. Hercberg Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. Am. J. Clinical Nutrition, August 1, 2006; 84(2): 395 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Saseen ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events Am. J. Health Syst. Pharm., July 1, 2005; 62(13): 1398 - 1405. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A Smith Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease Evid. Based Med., June 1, 2005; 10(3): 79 - 79. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Gross, M. J. de Azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori, and T. Zelmanovitz Diabetic Nephropathy: Diagnosis, Prevention, and Treatment Diabetes Care, January 1, 2005; 28(1): 164 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Persell and D. W. Baker Aspirin Use Among Adults With Diabetes: Recent Trends and Emerging Sex Disparities Arch Intern Med, December 13, 2004; 164(22): 2492 - 2499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gresele and R. Migliacci Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath? Eur. Heart J., October 2, 2004; 25(20): 1769 - 1771. [Full Text] [PDF]
|
|
|
|
|
|
G. G. Neri Serneri, S. Coccheri, E. Marubini, F. Violi, and for the Committees and the Investigators of the Dr Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study Eur. Heart J., October 2, 2004; 25(20): 1845 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Drzewoski and C. Watala Is Aspirin Resistance a Real Problem in People With Type 2 Diabetes?: Response to Sacco et al. Diabetes Care, May 1, 2004; 27(5): 1245 - 1246. [Full Text] [PDF]
|
|
|
|
|
|
M. Sacco, F. Pellegrini, M. C. Roncaglioni, F. Avanzini, G. Tognoni, and A. Nicolucci Aspirin Resistance in Diabetic Patients: Response to de Gaetano Diabetes Care, May 1, 2004; 27(5): 1246 - 1246. [Full Text] [PDF]
|
|
|
|
|
|
G. de Gaetano Aspirin Resistance in Diabetic Patients: Response to Sacco et al. Diabetes Care, May 1, 2004; 27(5): 1244 - 1245. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Colwell Aspirin for Primary Prevention of Cardiovascular Events in Diabetes Diabetes Care, December 1, 2003; 26(12): 3349 - 3350. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |